AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

The State of the Microbiome, 2019: Key Opportunities & Challenges - ResearchAndMarkets.com

February 22, 2019

DUBLIN--(BUSINESS WIRE)--Feb 22, 2019--The “The State of the Microbiome” report has been added to ResearchAndMarkets.com’s offering.

The State of the Microbiome provides an assessment of how the pharmaceutical industry perceives the state of the Microbiome, including the challenges associated with developing, launching, and manufacturing Microbiome therapeutics as well as where opportunity remains to invest in the Microbiome space.

The report is built on analyst expertise on the results of a 10 minutes survey of 158 Pharmaceuticals participants which was fielded from December 20, 2018 to January 7, 2019. Participants answered questions about the challenges they anticipate to impact the development, launch, manufacturing of Microbiome therapeutics.

Investment in Microbiome therapeutics is low across all therapy areas, but the infectious disease and gastrointestinal spaces are bringing in the highest levels of investment at 2.7 on a five-point scale. Identifying the mechanism of action was indicated by 27% of respondents as the most challenging aspect of developing Microbiome therapeutics. Also it is anticipated that the regulatory bodies may require drug developers to demonstrate the mechanisms of action of Microbiome therapeutics in order to gain regulatory approval.

Microbiome therapeutics was defined to include both live biotherapeutic products and products targeting the microbiome, excluding over the counter probiotics. As indicated, drug developers will face the challenge of manufacturing microbiome therapeutics using a cost-effective and scalable process that is consistent from batch to batch. Respondents indicated manufacturing (including consistency of strain) will be the most challenging aspect of launching microbiome therapeutics.

Scope

Reasons to Buy

Topics Covered

1 Study Design

1.1 Background, Objectives and Design

1.2 Respondent Mix - Geography

1.3 Respondent Mix - Seniority Level and Company Size

2 Executive Summary

2.1 Executive Summary

3 Microbiome Investment

3.1 Gastroenterology and Infectious Disease Mark the Most Active Therapy Areas

3.2 Infectious Disease and Gastroenterology Most Highly Invested Therapy Areas

3.3 A Closer Look at the Microbiome Pipeline

3.4 Microbiome Pipeline Targeting Gastrointestinal Indications and Infectious Diseases

3.5 A Closer Look at the Microbiome Pipeline Targeting Gastrointestinal Indications

3.6 A Closer Look at the Microbiome Pipeline Targeting Infectious Diseases

4 Challenges with Developing Microbiome Therapeutics

4.1 Identifying the Mechanism of Action Seen as a Major Challenge

4.2 Identifying the Mechanism of Action is Seen as the Most Challenging Factor

4.3 A Closer Look by Seniority Level

5 Challenges with Launching Microbiome Therapeutics

5.1 Manufacturing Identified as a Major Challenge

5.2 Manufacturing Identified as the Most Challenging Factor

5.3 A Closer Look by Seniority Level

6 Challenges with Manufacturing Microbiome Therapeutics

6.1 Dose Formulation is a Major Challenge

7 Key Findings and Recommendations

7.1 Summary of Key Findings

7.2 Recommendations

For more information about this report visit https://www.researchandmarkets.com/research/g3h84c/the_state_of_the?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190222005361/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Biopharmaceuticals

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/22/2019 11:12 AM/DISC: 02/22/2019 11:12 AM

http://www.businesswire.com/news/home/20190222005361/en